Trending NewsTrending NewsNASDAQ:AMGN Amgen (AMGN) Stock Price, News & Analysis $385.65 0.00 (0.00%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$385.69 +0.04 (+0.01%) As of 07:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amgen Stock (NASDAQ:AMGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amgen alerts:Sign Up Key Stats Today's Range$378.51▼$386.5050-Day Range$355.25▼$444.1252-Week Range$269.77▼$447.03Volume8.52 million shsAverage Volume2.79 million shsMarket Capitalization$208.49 billionP/E Ratio23.97Dividend Yield2.61%Price Target$381.32Consensus RatingHold Company Overview Amgen Inc. is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs. Amgen’s medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention. Through its acquisition of Horizon Therapeutics, Amgen also added medicines such as Tepezza, Krystexxa and Uplizna to its portfolio. Founded in 1980, Amgen is headquartered in Thousand Oaks, California, and serves patients and healthcare providers in the United States and international markets. The company’s products are distributed globally through healthcare systems, pharmacies and other channels. Robert A. Bradway has served as Amgen’s chairman and chief executive officer since 2012.AI Generated. May Contain Errors. Read More Amgen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreAMGN MarketRank™: Amgen scored higher than 68% of companies evaluated by MarketBeat, and ranked 240th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingAmgen has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, 11 buy ratings, 15 hold ratings, and 3 sell ratings.Upside/DownsideThe consensus price target for Amgen is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAmgen has been the subject of 22 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amgen's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth6.45% Earnings GrowthEarnings for Amgen are expected to grow by 6.45% in the coming year, from $22.94 to $24.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amgen is 23.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Amgen is 23.97, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.48.Price to Earnings Growth RatioAmgen has a PEG Ratio of 2.78. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmgen has a P/B Ratio of 23.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amgen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.42% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 5.62.Change versus previous monthShort interest in Amgen has recently increased by 7.76%, indicating that investor sentiment is decreasing significantly. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldAmgen pays a meaningful dividend of 2.61%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAmgen has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Amgen is 62.65%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Amgen will have a dividend payout ratio of 41.28% next year. This indicates that Amgen will be able to sustain or increase its dividend.Read more about Amgen's dividend. News and Social Media2.8 / 5News Sentiment0.49 News SentimentAmgen has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Amgen this week, compared to 10 articles on an average week.Search InterestOnly 27 people have searched for AMGN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows30 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 88% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,540,926.00 in company stock.Percentage Held by Insiders0.85% of the stock of Amgen is held by insiders.Percentage Held by Institutions76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amgen's insider trading history. Receive AMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMGN Stock News HeadlinesAmgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?September 19 at 8:55 AM | 247wallst.comBarclays Sticks to Its Hold Rating for Amgen (AMGN)September 18 at 10:53 PM | theglobeandmail.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 21 at 1:00 AM | Base Camp Trading (Ad)Amgen (AMGN) Gets a Buy from UBSSeptember 18 at 10:53 PM | theglobeandmail.comAmgen (AMGN) Surpasses Market Returns: Some Facts Worth KnowingSeptember 18 at 10:53 PM | finance.yahoo.comAmgen (AMGN) Stock Sees Modest Fair Value Lift As Analysts Weigh Pipeline RisksSeptember 18 at 10:53 PM | finance.yahoo.comA Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) TooSeptember 17, 2026 | finance.yahoo.comAmgen Drops 10% on a Trial It Didn't Even RunAMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.September 11, 2026 | marketbeat.comSee More Headlines AMGN Stock Analysis - Frequently Asked Questions How have AMGN shares performed this year? Amgen's stock was trading at $327.31 at the beginning of 2026. Since then, AMGN shares have increased by 17.8% and is now trading at $385.65. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings results on Tuesday, August, 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. The firm's revenue for the quarter was up 9.5% compared to the same quarter last year. Read the conference call transcript. Does Amgen have any subsidiaries? Amgen subsidiaries include these companies: TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more. Who are Amgen's major shareholders? Amgen's top institutional shareholders include BlackRock Inc. (9.15%), Primecap Management Co. CA (1.25%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.00%) and Bank of America Corp DE (0.94%). Insiders that own company stock include Murdo Gordon, David M Reese, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel and Rachna Khosla. View institutional ownership trends. How do I buy shares of Amgen? Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include NVIDIA (NVDA), Meta Platforms (META), Chevron (CVX), Verizon Communications (VZ), Bristol Myers Squibb (BMY), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/04/2026Record date for 9/11 Dividend8/21/2026Ex-Dividend for 9/11 Dividend8/21/2026Dividend Payable9/11/2026Today9/21/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 11 days, AMGN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AMGN CIK318154 Webwww.amgen.com Phone(805) 447-1000Fax805-447-1010Employees31,500Year Founded1980Price Target and Rating Average Price Target for Amgen$381.32 High Price Target$460.00 Low Price Target$200.00 Potential Upside/Downside-1.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage30 Analysts Profitability EPS (Trailing Twelve Months)$16.09 Trailing P/E Ratio23.97 Forward P/E Ratio16.81 P/E Growth2.78Net Income$7.71 billion Net Margins22.95% Pretax Margin27.00% Return on Equity124.14% Return on Assets13.18% Debt Debt-to-Equity Ratio4.44 Current Ratio1.37 Quick Ratio1.13 Sales & Book Value Annual Sales$36.75 billion Price / Sales5.67 Cash Flow$33.80 per share Price / Cash Flow11.41 Book Value$16.08 per share Price / Book23.98Miscellaneous Outstanding Shares540,630,000Free Float536,037,000Market Cap$208.49 billion OptionableOptionable Beta0.43 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:AMGN) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
